Rogers Campbell sold $237K of HTFL
Rogers Campbell (Chief Medical Officer) sold 9,219 shares of Heartflow, Inc. (HTFL) at $25.72 ($0.24M total) on 2026-07-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the CMO’s sale details: 9,219 shares at $25.72 on 2026-07-15, total value $237,112.68, with holdings after transaction of 88,731 shares and a stated 10b5-1 plan.
Market read
Traders may monitor HTFL for insider-selling cadence, but this specific disclosure is unlikely to drive a fundamental repricing by itself.
What to watch
The filing does not indicate whether additional sales are planned or whether the officer’s remaining holdings change materially over time; traders may need to compare with prior Form 4 patterns.
Background
The article is a SEC Form 4 insider transaction disclosure for Heartflow, Inc. (HTFL).
Ticker impact
Heartflow CMO Rogers Campbell sold 9,219 shares on 2026-07-15 for about $237.1K under a 10b5-1 plan, per Form 4.
Likely minimal near-term impact; any effect would be sentiment-driven and typically muted for 10b5-1 sales.
The filing discloses the transaction size, price ($25.72), and that it was executed under a pre-arranged 10b5-1 plan, which reduces interpretive weight versus discretionary selling.
Market effects
No direct sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerHeartflow, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderRogers Campbell
Chief Medical Officer who sold shares.
- trading mechanism10b5-1 plan
Pre-arranged plan that typically reduces interpretive weight of insider sales.
